Abstract: The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.

Abstract: The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.

Abstract: The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.

Abstract: The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.

Abstract: The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.

Abstract: The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.

Abstract: This invention relates to an unsaturated polyester resin composition characterized in that the resin composition comprises a. An unsaturated polyester resin comprising fumaric, maleic and/or itaconic building blocks, b. At least one vinyl ester as reactive diluent, c. An iron complex and/or salt, and d.

Abstract: The present invention relates to an unsaturated polyester resin comprising itaconate esters as reactive unsaturations, wherein the acid value of the resin is in the range of from 25 to 125 and the molar ratio of hydroxyl end groups and carboxylic acid end groups is in the range of from 0.33 to 3. In one embodiment, the molar ratio of hydroxyl end groups and carboxylic acid end groups is in the range of from 0.33 to 0.9. In another embodiment, the molar ratio of hydroxyl end groups and carboxylic acid end groups is in the range of from 1.1 to 3.

Abstract: The present invention relates to an unsaturated polyester resin comprising itaconate ester units as reactive unsaturation, wherein the resin comprises itaconate, citraconate and mesaconate ester units. Preferably, the resin comprises itaconate, citraconate and mesaconate ester units in an amount of from 40 to 90 mol % itaconate, from 2 to 30 mol % citraconate and from 5 to 40 mol % mesaconate in which 100 mol % is the total amount of itaconate, citraconate and mesaconate esters units.

Abstract: The present invention relates to an unsaturated polyester resin comprising itaconate esters as reactive unsaturations, wherein the acid value of the resin is in the range of from 25 to 125 and the molar ratio of hydroxyl end groups and carboxylic acid end groups is in the range of from 0.33 to 3. In one embodiment, the molar ratio of hydroxyl end groups and carboxylic acid end groups is in the range of from 0.33 to 0.9. In another embodiment, the molar ratio of hydroxyl end groups and carboxylic acid end groups is in the range of from 1.1 to 3.

Abstract: The present invention relates to an unsaturated polyester resin comprising itaconate ester units as reactive unsaturation, wherein the resin comprises itaconate, citraconate and mesaconate ester units. Preferably, the resin comprises itaconate, citraconate and mesaconate ester units in an amount of from 40 to 90 mol % itaconate, from 2 to 30 mol % citraconate and from 5 to 40 mol % mesaconate in which 100 mol % is the total amount of itaconate, citraconate and mesaconate esters units.